- Home
- AIM vs SMSI Comparison
AIM vs SMSI Comparison
Compare AIM & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- SMSI
- Stock Information
- Founded
- AIM 1966
- SMSI 1982
- Country
- AIM United States
- SMSI United States
- Employees
- AIM N/A
- SMSI N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- SMSI Computer Software: Prepackaged Software
- Sector
- AIM Health Care
- SMSI Technology
- Exchange
- AIM Nasdaq
- SMSI Nasdaq
- Market Cap
- AIM 16.6M
- SMSI 16.2M
- IPO Year
- AIM N/A
- SMSI 1995
- Fundamental
- Price
- AIM $0.26
- SMSI $0.95
- Analyst Decision
- AIM Strong Buy
- SMSI Strong Buy
- Analyst Count
- AIM 1
- SMSI 1
- Target Price
- AIM $5.00
- SMSI $20.00
- AVG Volume (30 Days)
- AIM 384.9K
- SMSI 546.4K
- Earning Date
- AIM 11-13-2024
- SMSI 11-06-2024
- Dividend Yield
- AIM N/A
- SMSI N/A
- EPS Growth
- AIM N/A
- SMSI N/A
- EPS
- AIM N/A
- SMSI N/A
- Revenue
- AIM $201,000.00
- SMSI $30,532,000.00
- Revenue This Year
- AIM N/A
- SMSI N/A
- Revenue Next Year
- AIM N/A
- SMSI $74.44
- P/E Ratio
- AIM N/A
- SMSI N/A
- Revenue Growth
- AIM 19.64
- SMSI N/A
- 52 Week Low
- AIM $0.21
- SMSI $0.52
- 52 Week High
- AIM $0.62
- SMSI $9.52
- Technical
- Relative Strength Index (RSI)
- AIM 42.56
- SMSI 46.48
- Support Level
- AIM $0.24
- SMSI $0.90
- Resistance Level
- AIM $0.29
- SMSI $1.05
- Average True Range (ATR)
- AIM 0.02
- SMSI 0.10
- MACD
- AIM 0.00
- SMSI -0.01
- Stochastic Oscillator
- AIM 48.33
- SMSI 11.35
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.